Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Abstract Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aleksandra Rajewska-Rager, Monika Dmitrzak-Weglarz, Pawel Kapelski, Natalia Lepczynska, Joanna Pawlak, Joanna Twarowska-Hauser, Maria Skibinska
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6b2167780c7c4f7184fa091448264fe6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b2167780c7c4f7184fa091448264fe6
record_format	dspace
spelling	oai:doaj.org-article:6b2167780c7c4f7184fa091448264fe62021-12-02T17:30:34ZLongitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders10.1038/s41598-021-91577-62045-2322https://doaj.org/article/6b2167780c7c4f7184fa091448264fe62021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91577-6https://doaj.org/toc/2045-2322Abstract Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential role of S100B in mood disorders in adolescents and young adults . In a prospective two-year follow-up study, peripheral levels of S100B were investigated in 79 adolescent/young adult patients (aged 14–24 years), diagnosed with mood disorders and compared with 31 healthy control subjects. A comprehensive clinical interview was conducted which focused on clinical symptoms and diagnosis change. The diagnosis was established and verified at each control visit. Serum S100B concentrations were determined. We detected: lower S100B levels in medicated patients, compared with those who were drug-free, and healthy controls; higher S100B levels in a depressed group with a family history of affective disorder; correlations between age and medication status; sex-dependent differences in S100B levels; and lack a of correlation between the severity of depressive or hypo/manic symptoms. The results of our study indicate that S100B might be a trait-dependent rather than a state-dependent marker. Due to the lack of such studies in the youth population, further research should be performed. A relatively small sample size, a lack of exact age-matched control group, a high drop-out rate.Aleksandra Rajewska-RagerMonika Dmitrzak-WeglarzPawel KapelskiNatalia LepczynskaJoanna PawlakJoanna Twarowska-HauserMaria SkibinskaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Aleksandra Rajewska-Rager Monika Dmitrzak-Weglarz Pawel Kapelski Natalia Lepczynska Joanna Pawlak Joanna Twarowska-Hauser Maria Skibinska Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders
description	Abstract Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential role of S100B in mood disorders in adolescents and young adults . In a prospective two-year follow-up study, peripheral levels of S100B were investigated in 79 adolescent/young adult patients (aged 14–24 years), diagnosed with mood disorders and compared with 31 healthy control subjects. A comprehensive clinical interview was conducted which focused on clinical symptoms and diagnosis change. The diagnosis was established and verified at each control visit. Serum S100B concentrations were determined. We detected: lower S100B levels in medicated patients, compared with those who were drug-free, and healthy controls; higher S100B levels in a depressed group with a family history of affective disorder; correlations between age and medication status; sex-dependent differences in S100B levels; and lack a of correlation between the severity of depressive or hypo/manic symptoms. The results of our study indicate that S100B might be a trait-dependent rather than a state-dependent marker. Due to the lack of such studies in the youth population, further research should be performed. A relatively small sample size, a lack of exact age-matched control group, a high drop-out rate.
format	article
author	Aleksandra Rajewska-Rager Monika Dmitrzak-Weglarz Pawel Kapelski Natalia Lepczynska Joanna Pawlak Joanna Twarowska-Hauser Maria Skibinska
author_facet	Aleksandra Rajewska-Rager Monika Dmitrzak-Weglarz Pawel Kapelski Natalia Lepczynska Joanna Pawlak Joanna Twarowska-Hauser Maria Skibinska
author_sort	Aleksandra Rajewska-Rager
title	Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders
title_short	Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders
title_full	Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders
title_fullStr	Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders
title_full_unstemmed	Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders
title_sort	longitudinal assessment of s100b serum levels and clinical factors in youth patients with mood disorders
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6b2167780c7c4f7184fa091448264fe6
work_keys_str_mv	AT aleksandrarajewskarager longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders AT monikadmitrzakweglarz longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders AT pawelkapelski longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders AT natalialepczynska longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders AT joannapawlak longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders AT joannatwarowskahauser longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders AT mariaskibinska longitudinalassessmentofs100bserumlevelsandclinicalfactorsinyouthpatientswithmooddisorders
_version_	1718380732335783936

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Ejemplares similares